Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 21Other hematologic neoplasm 13Thoracic 8Gynecologic 7Dermatologic 6Breast 5Myeloid 4Genitourinary 4Sarcoma 3Other solid neoplasm 3Gastrointestinal 3Tumor-Agnostic 2Plasma cell 2Head & Neck 2Endocrine 2NET 1CNS 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
belinostat × NET × Clear all
NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡